Medsintez Plant LLC

Medsintez Plant LLC is a strategic company located in Novouralsk, which plays a key role in ensuring the safety of drug supply in the Russian Federation. Founded in 2003, the plant produces a wide range of import-substituting pharmaceutical products and in 2020, it was included in the list of systemic companies of the country. In 2025, the plant was awarded the status of National Champion, confirming its leadership in the industry.

In 2007, the Medsintez Plant became the first pharmaceutical company in Russia being awarded the Russian Government Prize for Quality. The key factors of success include an in-house research and development center, modern quality control laboratories, and a team having deep expertise in organizing manufacture in accordance with international GMP standards.

The company's strategy is focused on the development and production of active pharmaceutical ingredients and high-tech drugs based on modern technology platforms, including organic, biotechnological, solid-phase peptide, and combined synthesis.

Drugs for the treatment of diabetes. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin ROSINSULIN and analogue human insulins ROSINSULIN ASPART R and ROSINSULIN GLARGINE made of our own APIs. In collaboration with Promomed Group of Companies, a full-cycle production of hypoglycemic drugs for treatment of type 2 diabetes, Liraglutide and Semaglutide (GLP-1), has been established.

Drugs for the Treatment of Infertility. Primapur® is the first Russian drug of recombinant human follicle-stimulating hormone for human infertility treatment, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur® is available in the form of an easy-to-use disposable injection pen. The company is developing a complete line of IVF medications to ensure drug safety in this area in Russia and allow independence from import supplies.

Antiviral drug TRIAZAVIRIN®. TRIAZAVIRIN® is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. TRIAZAVIRIN® is included in the clinical guidelines of the Russian Ministry of Health for the treatment of influenza and acute respiratory viral infections, and the prevention and treatment of COVID-19. A new dosage (100 mg) of TRIAZAVIRIN® for children aged 6-17 years was registered in 2025.

Veterinary Drugs. The plant also produces VINSUVET, the first Russian species-specific veterinary insulins for cats, dogs, and livestock.

Blood substitutes. The plant has established a full-cycle production of the world's first registered drug of recombinant human albumin for wide medical use.

Since 2024, Medsintez Plant has been implementing a major upgrade project aimed at expanding the production of drugs based on its own peptide and biotechnological substances (GLP-1 analogues, IVF medications). It will boost production volume and fully ensure independence for Russia in terms of essential groups of drugs.

One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.

Today, the Medsintez Plant addresses systemic challenges, such as mastering innovative technologies in line with international standards, expanding into the global market, developing the R&D center, creating IT solutions for pharmaceuticals and medical technologies, as well as providing ongoing personnel training and social support.

15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia

Тel.: +7 (34370) 2-50-61

e-mail: medsintez@mail.ru

www.medsintez.com